Keele, UK, 23 August 2006 – UK based Cobra Biomanufacturing Plc (AIM: CBF) today announces the appointment of Dr John Lovelady as Director of Manufacturing Operations for the Group. John replaces Dr Martin Comberbach who will be retained by the Company as a consultant. 

John was previously Vice President of Technical R&D and Manufacturing at  Gencell SA, Paris and prior to that as Vice President Operations at Genzyme Corporation UK. 

David Thatcher, Chief Executive of Cobra Biomanufacturing, commented:

“We are delighted that John Lovelady has joined Cobra to further strengthen our GMP production services. His unique blend of skill and experience will greatly enhance the quality and efficiency of our manufacturing services. ” 

-Ends- 

For further information:

Cobra Biomanufacturing Plc       

Tel: 44 (0) 1782 714 181

David Thatcher, Chief Executive              

Northbank Communications

Tel: 44 (0) 1260 296 500

Marc Egelhofer             

Buchanan Communications

Tel: 44 (0) 207 466 5000

Tim Anderson/Mark Court/Rebecca Dietrich    

Notes to Editors: 

About Cobra Biomanufacturing Plc:

Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products. Cobra was the first company to develop GMP (Good Manufacturing Practice) standard DNA manufacture in Europe, with specific expertise in DNA medicines. A range of unique, patented technologies, underpins this revenue generating business.

Cobra floated on the AIM market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK. www.cobrabio.com